M Pharmaceutical Inc. announced that its Board of Directors has made a decision to open a fully owned subsidiary company M Pharma Bulgaria Ltd. with a clear mandate to achieve registration of the Company's temporary controllable pseudobezoar technology Trimeo as a medical device in the European Union, and to obtain a CE Mark for it. M Pharma Bulgaria will collaborate with Medica AD (Bulgaria), a leading producer of CE certified medical materials in Eastern Europe, and with local vendors to achieve these objectives.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | +9,900.00% |
2018 | James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc | CI |
2018 | Callitas Health Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.53K | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- MPHMF Stock
- News Callitas Health Inc.
- M Pharmaceutical Inc. to Open a Fully Owned Subsidiary in Sofia, Bulgaria